Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Lithium Controls Central Nervous System Autoimmunity through Modulation of IFN-γ Signaling.
Gastrointestinal Tolerability of Delayed-Release Dimethyl Fumarate in a Multicenter, Open-Label Study of Patients with Relapsing Forms of Multiple Sclerosis (MANAGE).
Complex antibody profiling to predict clinical outcome in childhood ADS.
Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.
Teva and Active Biotech to continue with the development of NERVENTRA® (laquinimod) for multiple sclerosis following confirmation of CHMP opinion
The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.
Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis.
Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.
Receptos to Deliver Scientific Presentations Regarding RPC1063 at the 2014 American Academy of Neurology (AAN) Annual Meeting
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis.
Control of oxidative stress and inflammation in sickle cell disease with the Nrf2 activator dimethyl fumarate.
A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis
Receptos doses first patient in Phase 2 trial for RPC1063 in ulcerative colitis
Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients.
Phase 4 GI Tolerability Study of DMF in Patients With Relapsing Forms of MS in the US (MANAGE)
Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration.
Glatiramer acetate ameliorates inflammatory bowel disease in mice through the induction of Qa-1-restricted CD8⁺ regulatory cells.
Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes.
Immunological mechanisms underlying delayed-type hypersensitivity reactions to glatiramer acetate.
Inflammatory cortical demyelination in early multiple sclerosis.
Nephrotic Syndrome in a Multiple Sclerosis Patient Receiving Long-term Interferon Beta Therapy.
No Differences Observed among Multiple Clinical S1P1 Receptor Agonists (Functional Antagonists) in S1P1 Receptor Down-regulation and Degradation.
Teriflunomide (Aubagio) approved for use by the NHS in Scotland and Northern Ireland
[Experience of using genfaxon for treating patients with relapsing-remitting multiple sclerosis in the Russian Federation.]
Genzyme's Lemtrada™ Approved in Brazil for Treatment of Multiple Sclerosis

Pages